AstraZeneca Signs Licence Agreement With RQ Biotechnology for Monoclonal Antibodies Against COVID-19
May 18, 2022
AstraZeneca has entered into a licence agreement with RQ Biotechnology Ltd (RQ Bio) for a portfolio of early-stage monoclonal antibodies (mAbs) targeted against SARS-CoV-2, the virus that causes COVID-19. Under the agreement, AstraZeneca has acquired ...
chat_bubble0 Comment
visibility62 Views
RQ Bio Launches with Goal to Transform Treatment and Prevention of Viral Infectious Diseases Through Antibody Technologies
May 17, 2022
RQ Bio today emerges from stealth mode announcing its launch as a new UK-based biotechnology company following the completion of a successful licensing deal with AstraZeneca for RQ Bio’s existing mAbs against SARS-CoV-2. The Company, ...
chat_bubble0 Comment
visibility96 Views
LifeArc Co-founded Company RQ Bio Signs Licensing Agreement With AstraZeneca Worth Up to $157m Plus Royalties for Monoclonal Antibodies Against SARS-CoV-2
May 17, 2022
LifeArc today announced that RQ Biotechnology Ltd (RQ Bio), a company it co-founded, has signed a licensing agreement with AstraZeneca PLC (AZN). Under the terms of the agreement, RQ Bio has granted AstraZeneca an exclusive ...
chat_bubble0 Comment
visibility109 Views
Popular Posts
